Company news
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) news
Every Artiva Biotherapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
September 2, 2026
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 6, 2026
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 23, 2026
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webca...
June 8, 2026
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and ...
May 19, 2026
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 8, 2026
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
March 10, 2026
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
February 24, 2026
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
February 19, 2026
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Ta...
January 21, 2026
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmu...
November 12, 2025
Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 12, 2025
Artiva Biotherapeutics to Host Virtual Event Discussing Initial Safety and Translational Data in up to 32 Patients with Autoimmune Diseas...
November 3, 2025
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
October 30, 2025
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
October 16, 2025
Artiva Biotherapeutics to Participate in the Cantor Global Healthcare Conference 2025
August 25, 2025
Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights
August 6, 2025
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab ...
May 13, 2025
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
May 8, 2025
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgki...
April 28, 2025
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
April 8, 2025
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
March 24, 2025
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
February 20, 2025
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.
January 29, 2025
Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 12, 2024
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
October 22, 2024
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 29, 2024